U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma
FDA announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.